US Obesity Rates Plummet Amid Surge in Weight-Loss Medications
A new study by Gallup has revealed that the United States has seen an alarming decline in obesity rates, falling from nearly 40% in 2022 to 37% last year. The remarkable drop is attributed largely to a rise in the use of prescription weight-loss medications, including GLP-1 (glucagon-like peptide-1) injectables such as Ozempic and Wegovy.
According to Gallup's National Health and Well-Being Index survey, which polled nearly 17,000 adults across the country, the percentage of Americans using these blockbuster medications for weight loss has surged from 5.8% in February last year to a staggering 12.4% today. The resulting decline in obesity rates translates into around 8 million fewer obese adults nationwide.
However, this trend is offset by an alarming rise in diabetes rates, which have hit an all-time high of 13.8% in the same period, up from 13.4% last year and 12.8% two years ago. The disparity between declining obesity and unchanged diabetes rates suggests that several factors are at play.
While it is true that obesity increases one's risk of developing type 2 diabetes fourfold, not everyone who is obese will contract the condition, and some non-obese individuals may be diagnosed with diabetes as well. Moreover, diabetes is a chronic illness, which means that short-term reductions in obesity rates won't necessarily translate to decreased rates of diabetes.
Demographically, the survey also revealed striking differences in weight-loss medication use between men and women, as well as across age groups. While both genders have seen their usage rates double over the past year, women are using these medications at higher rates than men. The most significant reductions in obesity were observed among people aged 40-64, a demographic that also exhibits the highest rate of GLP-1 drug use.
Overall, these findings suggest that the United States is experiencing an unprecedented shift towards weight-loss medication adoption, which may have both positive and concerning implications for public health.
A new study by Gallup has revealed that the United States has seen an alarming decline in obesity rates, falling from nearly 40% in 2022 to 37% last year. The remarkable drop is attributed largely to a rise in the use of prescription weight-loss medications, including GLP-1 (glucagon-like peptide-1) injectables such as Ozempic and Wegovy.
According to Gallup's National Health and Well-Being Index survey, which polled nearly 17,000 adults across the country, the percentage of Americans using these blockbuster medications for weight loss has surged from 5.8% in February last year to a staggering 12.4% today. The resulting decline in obesity rates translates into around 8 million fewer obese adults nationwide.
However, this trend is offset by an alarming rise in diabetes rates, which have hit an all-time high of 13.8% in the same period, up from 13.4% last year and 12.8% two years ago. The disparity between declining obesity and unchanged diabetes rates suggests that several factors are at play.
While it is true that obesity increases one's risk of developing type 2 diabetes fourfold, not everyone who is obese will contract the condition, and some non-obese individuals may be diagnosed with diabetes as well. Moreover, diabetes is a chronic illness, which means that short-term reductions in obesity rates won't necessarily translate to decreased rates of diabetes.
Demographically, the survey also revealed striking differences in weight-loss medication use between men and women, as well as across age groups. While both genders have seen their usage rates double over the past year, women are using these medications at higher rates than men. The most significant reductions in obesity were observed among people aged 40-64, a demographic that also exhibits the highest rate of GLP-1 drug use.
Overall, these findings suggest that the United States is experiencing an unprecedented shift towards weight-loss medication adoption, which may have both positive and concerning implications for public health.
. One day we're seeing rates plummet and the next they're up again with diabetes on the rise. It's like, what's going on? 
I mean, I'm all for people taking control of their health and using meds to help them lose weight, but 12.4% of Americans are now using these GLP-1 injectables? That's wild 
.
. I'm not sure if this is good or bad, but it's definitely something to keep an eye on 
.
what's good?! 
pharmaceutical companies r rolling in dough from these GLP-1 injectables 
like, let's get to the root cause here... not just a quick fix 
anyway, i'm not gonna sit here and pretend like this isn't concerning... diabetes rates are through the roof and we're still dealing with the underlying issues. it's like, yeah, congrats on losing weight, but what about your pancreas? 
BUT AT THE SAME TIME, I'M WORRIED ABOUT THE RISE IN DIABETES RATES - 13.8% IS CRAZY HIGH!!! 
WHAT'S GOING ON WITH THAT? ARE PEOPLE TAKING THESE WEIGHT LOSS MEDICATIONS AND NOT THINKING ABOUT THE LONG-TERM EFFECTS ON THEIR HEALTH? 
. need more info on this before i start jumping to conclusions 
I know some people are struggling with their weight and it's great that meds like Ozempic and Wegovy are helping. But what about the flip side? Diabetes rates are through the roof! 
What's going on with our healthcare system?! 
I need more answers than just "hey, let's prescribe more meds" 
... we gotta consider other factors like diet & exercise too 
It's like the old adage goes: "you can't take it with you, but you can get a sweet deal on some Ozempic" 
. But seriously, what does this say about our healthcare system? Are we treating the symptoms or the problem itself? And let's not forget the elephant in the room - insurance companies making a killing off these new meds 
but at the same time kinda relieved that I don't gotta worry about gettin' diabetes now 
anyways, this is wild, 12.4% of people in the US are usin' these meds, that's like a whole lotta needles stickin' in arms 
On one hand, it's amazing to see so many people taking control of their health - 12.4% of adults now use these meds? That's a huge jump! 
and nobody's talking about the elephant in the room - diabetes! 13.8% is straight-up crazy 
I get that obesity increases your risk of type 2 diabetes, but come on, what's going on here? Are these weight loss meds just a Band-Aid solution for a much bigger problem? 
without considering the consequences. I'm all for people wanting to lose weight, but let's not get ahead of ourselves here 
.
But at the same time, it's kinda scary that diabetes rates are shooting up too... 
Like, we gotta be careful what we're wishing for, right? 
Let's just hope this trend keeps going and we can all live healthier lives! 
glp-1 injectables r the real deal apparently 12% of ppl in america are using them and it's had a huge impact on obesity rates. but at the same time theres this weird disparity between obesity and diabetes rates...like whats going on there?